CTSA Program KL2 Scholar in the News:

Understanding and treating cardiovascular effects of cancer treatments in women with breast cancer

- BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines have no significant differences in cardiac function compared to women with history of sporadic breast cancer
- In a prospective multicenter pilot study we demonstrated cardiac safety of HER2 targeted therapy in patients with HER2-positive breast cancer and reduced left ventricular function

“Multidisciplinary collaboration between cardiology and oncology offers an opportunity to advance care and improve outcomes of women with breast cancer”

Ana Barac, MD, PhD